Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the ...
After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in ...
Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice ...
In the first opportunity for industry watchers to compare the two approved TROP2 antibody-drug conjugates side by side in ...
Tiragolumab plus Tecentriq did not improve progression-free survival compared to Imfinzi in stage 3 NSCLC post-cCRT. Median progression-free survival and overall survival were similar between the ...
A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated ...
Tiragolumab plus atezolizumab did not improve progression-free survival compared to durvalumab in stage III NSCLC patients post-cCRT. Median progression-free survival and overall survival were similar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback